Skip to main content

Table 3 Skin status at one-year follow-up examination

From: The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study

  IM IFNβ-1a
(n = 73)
SC IFNβ-1b
(n = 104)
SC IFNβ-1a
(n = 154)
SC GA
(n = 14)
Overall
(N = 345)
Necrosis, n (%) 0 (0) 5 (4.8) 5 (3.2) 0 (0) 10 (2.9)
Number of occurrences      
   1 0 3/5 (60.0) 2/5 (40.0) 0 5/10 (50.0)
   2 0 1/5 (20.0) 2/5 (40.0) 0 3/10 (30.0)
   Unknown 0 1/5 (20.0) 1/5 (20.0) 0 2/10 (20.0)
Severity      
   Mild 0 3/5 (60.0) 1/5 (20.0) 0 4/10 (40.0)
   Moderate 0 0 3/5 (60.0) 0 3/10 (30.0)
   Severe 0 1/5 (20.0) 0 0 1/10 (10.0)
   Unknown 0 1/5 (20.0) 1/5 (20.0) 0 2/10 (20.0)
Lipoatrophy, n (%) 0 (0)a 9 (8.7) 23 (15.0)b 1 (7.1) 33 (9.6)
Number of occurrences      
   1 0 3/9 (33.3) 4/23 (17.4) 0 7/33 (21.2)
   2 0 2/9 (22.2) 11/23 (47.8) 1/1 (100) 14/33 (42.4)
   3 0 3/9 (33.3) 3/23 (13.0) 0 6/33 (18.2)
   4 0 0 1/23 (4.3) 0 1/33 (3.0)
   ≥5 0 1/9 (11.1) 3/23 (13.0) 0 4/33 (12.1)
   Unknown 0 0 1/23 (4.3) 0 1/33 (3.0)
Severity      
   Mild 0 6/9 (66.7) 11/23 (47.8) 0 17/33 (51.5)
   Moderate 0 2/9 (22.2) 6/23 (26.1) 1/1 (100) 9/33 (27.3)
   Severe 0 1/9 (11.1) 1/23 (4.3) 0 2/33 (6.1)
   Unknown 0 0 5/23 (21.7) 0 5/33 (15.2)
  1. a P = 0.011 vs SC IFNβ-1b; P < 0.0001 vs SC IFNβ-1a.
  2. bLipoatrophy status was not collected for 1 SC IFNβ-1a patient (n = 153).